idea-003 · stage 6 · yours

ctDNA Assay Reference Panel

wrapped status: wrapped packet f47d8efc409c

Nothing on this page is a recommendation. It gathers what the packet already says into the order a decision reads it. Wrapped means finished enough to read, not judged.

The bet

A laboratory running a tumor-informed MRD (molecular residual disease) assay has to show, before it reports patients and then on every run, that the assay still detects tumor DNA at the fractions it claims. CLIA (Clinical Laboratory Improvement Amendments) requires control procedures that monitor the complete analytic process claim 7verified. It names no material for doing so claim 76verified, claim 77verified. So labs today make their own contrived controls, or dilute the one incumbent product with sub-0.1% levels, which is purified DNA in buffer claim 111unconfirmed, into their own plasma. The bet is that such a lab pays $400-$900 a vial for a single-use daily control, and $1,500-$3,000 for a validation panel claim 149unconfirmed. The material is built in pooled donor plasma, so it goes through extraction alongside the patient samples claim 187unconfirmed. It carries a stated uncertainty at every level, and it is listed as a Class II (FDA device class II) QC (quality control) device under product code SCU (subcutaneous), which FDA (US Food and Drug Administration) marks 510(k) (premarket notification)-exempt claim 131verified. The recurring money is the daily control claim 151unconfirmed. That line is the reason P2 clinical QC material at launch chose a clinical-QC label over an RUO (research use only) one, and it is also the line the RUO label disclaimed. The buyers are the thirty to sixty US labs running or developing these assays claim 12unconfirmed. The structural attraction is that no incumbent sells a plasma-matrix level below 0.1% claim 188unconfirmed. The structural danger is that the whole bet sits on one sentence, and the sentence has to satisfy three parties at once. FDA has to read it as exempt. The physics has to support its per-vial claims. A tumor-informed lab has to be able to run a control whose variants are not its patient's.

Evidence

verifiedunconfirmedrefutednot yet checked

32/192

verified

158

unconfirmed

refuted

4/4

core factors

The claim ledger →

First in the assessment's queue

criticalB1 A cancer-testing laboratory has to be willing to buy an outside quality- control sample and run it with every batch, build and maintain a dedicated test panel for it, accept it as meeting its quality rules, and pay for it rather than make its own. If labs will not, there is no customer.
Precisely: A laboratory running a tumor-informed MRD assay can and will run a purchased third-party control as its routine run-by-run control. That means designing and maintaining a dedicated panel against the control's certified variants, accepting that panel as meeting its control requirement, and paying for it instead of diluting incumbent material or making its own
fatal if false
cheap to find out
Adjacent cases: not asked — nobody has said who outside this opportunity already ran this experiment.
criticalB5 There have to be enough laboratories, buying enough vials a year, at a price at or above today's incumbent, to cover the full cost including a permanent quality system. If the volumes or prices are too low, there is no business.
Precisely: It is a business. Enough labs, enough recurring control volume not held by one laboratory, and prices at or above the incumbent anchor clear the fully loaded cost, including a fixed quality-system layer, at planning volumes of about 50 panels and 2,000 vials a year
fatal if false
project to find out
Adjacent cases: not asked — nobody has said who outside this opportunity already ran this experiment.
highB8 Something beyond the lab's own preference, a payer rule, an accreditation checklist, an industry consensus, or test revenue big enough to fund it, has to push labs toward buying characterised outside controls. If nothing does, adoption is slower and the business thinner.
Precisely: Something outside the lab's own preference pulls it toward characterized third-party material. Candidates are a payer technical assessment, the CAP checklist, the BLOODPAC consensus, or downstream test revenue large enough to fund QC spend
costly if false
cheap to find out

The whole assessment →

The chairs

Regulatory: conditionalClinical & Scientific: conditionalMarket Access: conditionalTechnology & R&D: conditionalOperations & NPI: conditionalLegal & IP: conditionalCommercial: conditional

7 of 7 departments have stated a position. The argument →

Still open

34 open question(s) between departments

What a decision does

Approve sets status: shortlisted — the only thing that lets /diligence start.
Reject or defer is recorded with your note; nothing further is unlocked.

Your decision

You are reading packet f47d8efc409c.

Deciding from this page is not built yet — it needs a signature only your own device can make, so that no agent can produce one. Until then a decision is recorded by engine/scripts/human_decision.py, run by you in your own terminal.

Ask something before deciding ↗

Words on this page8 abbreviation(s) and code(s), with what each stands for — copied from _shared/plain-language.md

510(k): premarket notification — the FDA route for a device shown to be as safe and effective as one already on the market; months, no clinical trial as a rule
Class II: FDA device class II — moderate-risk devices, usually cleared by 510(k)
CLIA: Clinical Laboratory Improvement Amendments — the US rules a clinical laboratory must meet to report test results on patients
FDA: US Food and Drug Administration — the US regulator that clears or approves a device before it can be sold
MRD: molecular residual disease — cancer left behind after treatment, too little to see on a scan, detected through DNA in the blood
QC: quality control — the samples and checks a laboratory runs to prove its test is still working
RUO: research use only — a labelling status that keeps a product out of patient diagnosis; no FDA review, no clinical claims
SCU: subcutaneous — under the skin

Generated from knowledge-base/candidates/idea-003.md by engine/scripts/build_review.py on 2026-10-04. This page is a view — edit the source file and rebuild, never edit here.